Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry

Penetrance estimates of the leucine‐rich repeat kinase 2 (LRRK2) p.G2019S mutation for PD vary widely (24%‐100%). The p.G2019S penetrance in individuals of Ashkenazi Jewish ancestry has been estimated as 25%, adjusted for multiple covariates. It is unknown whether penetrance varies among different ethnic groups. The objective of this study was to estimate the penetrance of p.G2019S in individuals of non‐Ashkenazi Jewish ancestry and compare penetrance between Ashkenazi Jews and non‐Ashkenazi Jews to age 80.

[1]  K. Marder,et al.  Estimation of genetic risk function with covariates in the presence of missing genotypes , 2017, Statistics in medicine.

[2]  E. Tolosa,et al.  Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[3]  D. Zeng,et al.  Efficient Estimation of Nonparametric Genetic Risk Function with Censored Data. , 2015, Biometrika.

[4]  K. Marder,et al.  Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium , 2015, Neurology.

[5]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[6]  J. Trinh,et al.  A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism , 2014, Neurobiology of Aging.

[7]  P. Mazzoni,et al.  Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[8]  Ellen Sidransky,et al.  The link between the GBA gene and parkinsonism , 2012, The Lancet Neurology.

[9]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[10]  C. Magnani,et al.  Kin‐cohort analysis of LRRK2‐G2019S penetrance in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[11]  Geert Molenberghs,et al.  Random Effects Models for Longitudinal Data , 2010 .

[12]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[13]  P. Matthews,et al.  LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study , 2008, The Lancet Neurology.

[14]  Nir Giladi,et al.  The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease , 2007, Neurology.

[15]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[16]  K. Marder,et al.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease , 2006, Neurology.

[17]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[18]  E D Louis,et al.  Accuracy of family history data on Parkinson’s disease , 2003, Neurology.

[19]  S Wacholder,et al.  The kin-cohort study for estimating penetrance. , 1998, American journal of epidemiology.

[20]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.